Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022

Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its second quarter 2022 financial results on July 27, 2022, at 7:00 a.m. ET. Following the release, a conference call and live webcast will take place at 8:00 a.m. ET. Interested participants can register here.

The live webcast can be accessed on Teva's website. A replay will be available within 24 hours.

Positive

• Teva's extensive portfolio includes over 3,500 products across therapeutic areas.
• Around 200 million people utilize Teva medicines daily, reflecting its global reach.

Negative

• The press release contains forward-looking statements subject to risks and uncertainties that could significantly impact future results.

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: http://ir.tevapharm.com/.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This document and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005707/en/

IR Contacts



Ran Meir

(267) 468-4475



Yael Ashman

+972 (3) 914 8262



PR Contacts



Kelley Dougherty

(973) 832-2810



Eden Klein

+972 (3) 906 2645

Source: Teva Pharmaceutical Industries Limited

FAQ

When will Teva announce its Q2 2022 financial results?

Teva will announce its Q2 2022 financial results on July 27, 2022, at 7:00 a.m. ET.

What time is the Teva Q2 2022 conference call?

The conference call will take place on July 27, 2022, at 8:00 a.m. ET.

Where can I listen to the Teva Q2 2022 earnings call?

The call will be available via live webcast on Teva's website.

How can I participate in the Teva Q2 2022 earnings call?

Participants must register in advance to obtain the necessary phone number and personal pin.